Italia markets close in 5 minutes

Terumo Corporation (4543.T)

Tokyo - Tokyo Prezzo differito. Valuta in JPY.
Aggiungi a watchlist
2.697,50-76,50 (-2,76%)
Alla chiusura: 03:15PM JST
Schermo intero
Chiusura precedente2.774,00
Aperto2.797,50
Denaro2.690,00 x 0
Lettera2.698,00 x 0
Min-Max giorno2.686,00 - 2.798,00
Intervallo di 52 settimane1.856,00 - 3.014,50
Volume2.406.500
Media Volume3.589.325
Capitalizzazione4,005T
Beta (5 anni mensile)0,50
Rapporto PE (ttm)37,69
EPS (ttm)71,57
Prossima data utili07 ago 2024 - 12 ago 2024
Rendimento e dividendo (futuro)26,00 (0,94%)
Data ex dividendo27 set 2024
Stima target 1A3.030,00
  • GlobeNewswire

    Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update

    U.S. Food and Drug Administration (“FDA”) granted Investigational Device Exemption (“IDE”) approval with conditions for Virtue SAB® coronary in-stent restenosis (“ISR”) U.S. pivotal study (in collaboration with Terumo Corporation (“Terumo”)); study expected to start before the end of 2023BackBeat CNT™ global pivotal study in hypertensive pacemaker patients (in collaboration with Medtronic) on track for initiation in the second half of 2023 NEW HOPE, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Orchest

  • GlobeNewswire

    Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis

    Virtue® Sirolimus AngioInfusion Balloon (“SAB”) is the only non-coated angioplasty system providing protected delivery of extended release sirolimus under clinical investigation worldwideVirtue ISR-US pivotal study focused on coronary in-stent restenosis (“ISR”), a difficult-to-treat and serious complication of coronary stenting, currently expected to start before the end of 2023Strategic partnership with Terumo Corporation (“Terumo”) targets coronary ISR and multiple additional vascular indicat